WO2014155300A3 - Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1 - Google Patents

Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1 Download PDF

Info

Publication number
WO2014155300A3
WO2014155300A3 PCT/IB2014/060155 IB2014060155W WO2014155300A3 WO 2014155300 A3 WO2014155300 A3 WO 2014155300A3 IB 2014060155 W IB2014060155 W IB 2014060155W WO 2014155300 A3 WO2014155300 A3 WO 2014155300A3
Authority
WO
WIPO (PCT)
Prior art keywords
inhibitors
amine derivatives
tak
pyrimidine amine
substitued
Prior art date
Application number
PCT/IB2014/060155
Other languages
English (en)
Other versions
WO2014155300A2 (fr
Inventor
Vamsee Krishna Chintakunta
Vidyadhar Paradkar
Original Assignee
Aurigene Discovery Technologies Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurigene Discovery Technologies Limited filed Critical Aurigene Discovery Technologies Limited
Publication of WO2014155300A2 publication Critical patent/WO2014155300A2/fr
Publication of WO2014155300A3 publication Critical patent/WO2014155300A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La présente invention concerne des dérivés pyrimidine aminée substitués de la formule (I) et leurs sels pharmaceutiquement acceptables, ou des stéréoisomères pharmaceutiquement acceptables de ceux-ci, qui sont utiles en tant qu'inhibiteurs de TAK1. (I) En particulier, l'invention concerne également leur procédé de préparation, des compositions pharmaceutiques les comprenant, et leur utilisation pour le traitement et la prévention de maladies ou de troubles, en particulier leur utilisation dans des maladies ou troubles associés en tant qu'inhibiteurs de TAK1.
PCT/IB2014/060155 2013-03-28 2014-03-26 Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1 WO2014155300A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1403/CHE/2013 2013-03-28
IN1398CH2013 2013-03-28
IN1398/CHE/2013 2013-03-28
IN1403CH2013 2013-03-28

Publications (2)

Publication Number Publication Date
WO2014155300A2 WO2014155300A2 (fr) 2014-10-02
WO2014155300A3 true WO2014155300A3 (fr) 2015-04-02

Family

ID=51625558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2014/060155 WO2014155300A2 (fr) 2013-03-28 2014-03-26 Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1

Country Status (1)

Country Link
WO (1) WO2014155300A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3514153B1 (fr) 2017-01-26 2021-07-07 Hanmi Pharm. Co., Ltd. Composé pyrimidine et son utilisation pharmaceutique
AU2019203034B1 (en) 2018-07-25 2019-09-26 Hanmi Pharm. Co., Ltd. Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
KR101954370B1 (ko) 2018-07-25 2019-03-05 한미약품 주식회사 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
WO2020180959A1 (fr) 2019-03-05 2020-09-10 Incyte Corporation Composés de pyrazolyl pyrimidinylamine en tant qu'inhibiteurs de cdk2
US11919904B2 (en) 2019-03-29 2024-03-05 Incyte Corporation Sulfonylamide compounds as CDK2 inhibitors
WO2020223558A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Composés aminés tricycliques en tant qu'inhibiteurs de cdk2
WO2020223469A1 (fr) 2019-05-01 2020-11-05 Incyte Corporation Dérivés de n-(1-(méthylsulfonyl)pipéridin-4-yl)-4,5-di hydro-1h-imidazo[4,5-h]quinazolin-8-amine et composés apparentés utilisés en tant qu'inhibiteurs de kinase 2 dépendante des cyclines (cdk2) pour le traitement du cancer
EP4013750A1 (fr) 2019-08-14 2022-06-22 Incyte Corporation Composés imidazolyl-pyrimidinylamines utilisés comme inhibiteurs de la cdk2
EP4041731A1 (fr) 2019-10-11 2022-08-17 Incyte Corporation Amines bicycliques utilisées en tant qu'inhibiteurs de cdk2
CN114380806B (zh) * 2022-03-24 2022-06-10 中国药科大学 2-氨基-4-吲哚基嘧啶类化合物及其制备方法与应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045941A1 (fr) * 2001-11-21 2003-06-05 Celltech R & D Limited Derives de pyridine et de pyrimidine
US20080300267A1 (en) * 2005-05-16 2008-12-04 Barun Okram Compounds and Compositions as Protein Kinase Inhibitors
WO2012021444A1 (fr) * 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Sel de bésylate d'un inhibiteur de btk

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003045941A1 (fr) * 2001-11-21 2003-06-05 Celltech R & D Limited Derives de pyridine et de pyrimidine
US20080300267A1 (en) * 2005-05-16 2008-12-04 Barun Okram Compounds and Compositions as Protein Kinase Inhibitors
WO2012021444A1 (fr) * 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Sel de bésylate d'un inhibiteur de btk

Also Published As

Publication number Publication date
WO2014155300A2 (fr) 2014-10-02

Similar Documents

Publication Publication Date Title
WO2014155300A3 (fr) Dérivés pyrimidine aminée substitués en tant qu'inhibiteurs de tak-1
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
MA39986A (fr) Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MD20160106A2 (ro) Compuşi aril sau heteroaril biciclici condensaţi şi utilizarea acestora ca inhibitori IRAK4
WO2015200680A8 (fr) Inhibiteurs de prmt5 et leurs utilisations
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
WO2014153100A3 (fr) Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
WO2014153235A3 (fr) Inhibiteurs de l'arginine méthyltransférase et utilisations de ceux-ci
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
WO2014028600A3 (fr) Composés 3-aminocycloalkyl utilisés en tant qu'inhibiteurs de rorgammat et utilisations de ceux-ci
WO2013163190A8 (fr) Inhibiteurs d'adn pk
MY175854A (en) Novel quinolone derivatives
WO2013192049A3 (fr) Inhibiteurs de 1,2,4-triazine-6-carboxamide kinase
NZ706591A (en) Oxazolidin-2-one-pyrimidine derivatives
PH12017500595A1 (en) Aldosterone synthase inhibitors
MY180844A (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
PH12017500089B1 (en) Aldosterone synthase inhibitors
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
PH12015502746A1 (en) Prodrug derivatives of substituted triazolopyridines
MX2013013436A (es) Derivados de indol sustituidos para el tratamiento de transtornos inmunologicos.
WO2013155465A8 (fr) Dérivés de xanthine substituée
MX2015012350A (es) Derivados de la 5-amino-quinolina-8-carboxamida como agonistas del receptor 5ht4.
EA201600411A1 (ru) Производные пиперидина для применения при лечении или профилактики психиатрических и неврологических состояний
IN2013MU03838A (fr)

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 14775627

Country of ref document: EP

Kind code of ref document: A2